Literature DB >> 7612223

Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.

G Trinchieri1.   

Abstract

Interleukin-12 (IL-12) is a heterodimeric cytokine produced mostly by phagocytic cells in response to bacteria, bacterial products, and intracellular parasites, and to some degree by B lymphocytes. IL-12 induces cytokine production, primarily of IFN-gamma, from NK and T cells, acts as a growth factor for activated NK and T cells, enhances the cytotoxic activity of NK cells, and favors cytotoxic T lymphocyte generation. In vivo IL-12 acts primarily at three stages during the innate resistance/adaptive immune response to infection: 1. Early in the infection, IL-12 is produced and induces production from NK and T cells of IFN-gamma, which contributes to phagocytic cell activation and inflammation; 2. IL-12 and IL-12-induced IFN-gamma favor Th1 cell differentiation by priming CD4+ T cells for high IFN-gamma production; and 3. IL-12 contributes to optimal IFN-gamma production and to proliferation of differentiated Th1 cells in response to antigen. The early preference expressed in the immune response depends on the balance between IL-12, which favors Th1 responses, and IL-4, which favors Th2 responses. Thus, IL-12 represents a functional bridge between the early nonspecific innate resistance and the subsequent antigen-specific adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7612223     DOI: 10.1146/annurev.iy.13.040195.001343

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  526 in total

Review 1.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.

Authors:  G Haskó; C Szabó
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 3.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

4.  Activation of mononuclear cells by interleukin-12: an in vivo study in chimpanzees.

Authors:  F N Lauw; A A te Velde; P E Dekkers; P Speelman; J M Aerts; C E Hack; S J van Deventer; T van der Poll
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

Review 5.  Interleukin 12 and innate molecules for enhanced mucosal immunity.

Authors:  P N Boyaka; J W Lillard; J McGhee
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

6.  Natural T cells: cranking up the immune system by prompt cytokine secretion.

Authors:  S Joyce
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 7.  Th1/Th2 balance in atopy.

Authors:  T Biedermann; M Röcken
Journal:  Springer Semin Immunopathol       Date:  1999

Review 8.  Educating T cells: early events in the differentiation and commitment of cytokine-producing CD4+ and CD8+ T cells.

Authors:  A Kelso
Journal:  Springer Semin Immunopathol       Date:  1999

9.  Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis.

Authors:  C Jiang; D M Magee; R A Cox
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 10.  Future prospects for anti-cytokine treatment.

Authors:  M Feldmann; J Miotla; E Paleolog; R Williams; A M Malfait; P Taylor; F M Brennan; R N Maini
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.